Heart Failure
Serious cardiovascular events rare after CAR T-cell therapy
A meta-analysis of patients who underwent chimeric antigen receptor T-cell therapy for advanced blood cancers showed low prevalence of cardiovascular adverse events.
Benefits of finerenone consistent in HF regardless if EF midrange or preserved
New data from the FINEARTS-HF trial show that finerenone improved outcomes in patients with HF compared with placebo across the entire midrange and preserved ejection fraction ranges.
Finerenone benefits in HFpEF may be greater in patients with recent worsening HF
In patients with HF and ejection fraction 40% or greater, the absolute risk reduction for total worsening HF events and CV death with finerenone vs. placebo was greatest in those with recent worsening HF, new data from FINEARTS-HF show.
HFSA scientific meeting canceled due to risks from Hurricane Helene
The Heart Failure Society of America Annual Scientific Meeting scheduled to take place Sept. 27 to 30 in Atlanta has been canceled following declaration of a State of Emergency by the governor of Georgia due to Hurricane Helene.
Older cancer survivors at elevated risk for cardiovascular disease
Older cancer survivors exhibited increased risk for cardiovascular disease than cancer-free individuals of the same age, according to a secondary analysis of a randomized study.
Neighborhood socioeconomic status linked with heart failure, death for patients with CKD
Neighborhood socioeconomic status was linked with incident heart failure among patients with chronic kidney disease who had more preserved kidney function, study results showed.
Finerenone benefits in heart failure consistent regardless of diabetes status
In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone improved outcomes compared with placebo regardless of baseline diabetes status, according to new data from the FINEARTS-HF trial.
All-cause mortality lower with use of allopurinol, febuxostat for adults on hemodialysis
Allopurinol and febuxostat were both associated with lower all-cause mortality when used by adults undergoing hemodialysis in Japan; allopurinol also lowered risk of death from CVD events, according to study data.
Semaglutide cuts risk for worsening heart failure, CV death among adults with HFpEF
Semaglutide cut the risk for worsening heart failure and CV death for adults with HF with preserved ejection fraction, according to data presented at the European Society of Cardiology Congress and simultaneously published in The Lancet.
TEER noninferior to surgery in patients with heart failure, mitral regurgitation
In patients with HF and secondary mitral regurgitation, transcatheter edge-to-edge repair was noninferior to mitral valve surgery for efficacy and was linked with fewer safety endpoint events, according to data from the MATTERHORN trial.